PHASE 1B/2 STUDY OF 177LU GIRENTUXIMAB PLUS CABOZANTINIB AND NIVOLUMAB IN TREATMENT-NAIVE PATIENTS WITH ADVANCED CLEAR CELL RCC

The Univeristy Of Texas M.D. Anderson Cancer Center

Investigators